Uncategorized Guest User 10/2/12 Uncategorized Guest User 10/2/12 "The FDA as a Global Actor": a Summary Report Read More Advocacy at a Glance Guest User 9/28/12 Advocacy at a Glance Guest User 9/28/12 Meatless Monday and the Washington Monument syndrome Read More Advocacy at a Glance Guest User 9/23/12 Advocacy at a Glance Guest User 9/23/12 Sequestration Update and more Read More Analysis and Commentary Guest User 9/23/12 Analysis and Commentary Guest User 9/23/12 The Impact of Sequestration: An Update and Commentary Read More Uncategorized Guest User 9/14/12 Uncategorized Guest User 9/14/12 OMB Report Suggests $318 Million Loss to FDA From Sequestration Read More Advocacy at a Glance Guest User 9/14/12 Advocacy at a Glance Guest User 9/14/12 Sequester Transparency Report and more Read More Analysis and Commentary Guest User 9/14/12 Analysis and Commentary Guest User 9/14/12 A Large and Unequal Hit on the FDA Read More What's in the Media? Guest User 9/11/12 What's in the Media? Guest User 9/11/12 Hamburg Speaks on Effect of Sequester on User Fees Read More What's in the Media? Guest User 9/10/12 What's in the Media? Guest User 9/10/12 More on Sequestration and the FDA Budget for FY 13 Read More Analysis and Commentary Guest User 9/8/12 Analysis and Commentary Guest User 9/8/12 Of 6-Month CRs and the Perils of Sequestration Read More Advocacy at a Glance Guest User 9/8/12 Advocacy at a Glance Guest User 9/8/12 Congress Back in Session Next Week and more Read More Uncategorized Guest User 9/4/12 Uncategorized Guest User 9/4/12 Sequestration Potentially to INCLUDE Industry User Fees Read More Analysis and Commentary Guest User 8/24/12 Analysis and Commentary Guest User 8/24/12 Bringing IT at the FDA into the 21st Century Read More Advocacy at a Glance Guest User 8/24/12 Advocacy at a Glance Guest User 8/24/12 Update on FY 13 Continuing Resolution and Congressional Deficit Negotiations and more Read More Uncategorized Guest User 8/24/12 Uncategorized Guest User 8/24/12 Erratum Read More Analysis and Commentary Guest User 8/20/12 Analysis and Commentary Guest User 8/20/12 Relative -- as Opposed to Absolute -- Levels of FDA Funding Read More Analysis and Commentary Guest User 8/13/12 Analysis and Commentary Guest User 8/13/12 Honest assessment of priorities: a Congressional imperative for FDA Read More Advocacy at a Glance Guest User 8/13/12 Advocacy at a Glance Guest User 8/13/12 President Obama signs Sequestration Transparency Act and more Read More Advocacy at a Glance Guest User 8/8/12 Advocacy at a Glance Guest User 8/8/12 Betting on a 6-Month-Long, CR-based Compromise Read More Advocacy at a Glance Guest User 8/8/12 Advocacy at a Glance Guest User 8/8/12 Office of Management and Budget Guidance to Government Agencies Regarding Potential Sequestration and more Read More Newer Posts Older Posts
Uncategorized Guest User 10/2/12 Uncategorized Guest User 10/2/12 "The FDA as a Global Actor": a Summary Report Read More
Advocacy at a Glance Guest User 9/28/12 Advocacy at a Glance Guest User 9/28/12 Meatless Monday and the Washington Monument syndrome Read More
Advocacy at a Glance Guest User 9/23/12 Advocacy at a Glance Guest User 9/23/12 Sequestration Update and more Read More
Analysis and Commentary Guest User 9/23/12 Analysis and Commentary Guest User 9/23/12 The Impact of Sequestration: An Update and Commentary Read More
Uncategorized Guest User 9/14/12 Uncategorized Guest User 9/14/12 OMB Report Suggests $318 Million Loss to FDA From Sequestration Read More
Advocacy at a Glance Guest User 9/14/12 Advocacy at a Glance Guest User 9/14/12 Sequester Transparency Report and more Read More
Analysis and Commentary Guest User 9/14/12 Analysis and Commentary Guest User 9/14/12 A Large and Unequal Hit on the FDA Read More
What's in the Media? Guest User 9/11/12 What's in the Media? Guest User 9/11/12 Hamburg Speaks on Effect of Sequester on User Fees Read More
What's in the Media? Guest User 9/10/12 What's in the Media? Guest User 9/10/12 More on Sequestration and the FDA Budget for FY 13 Read More
Analysis and Commentary Guest User 9/8/12 Analysis and Commentary Guest User 9/8/12 Of 6-Month CRs and the Perils of Sequestration Read More
Advocacy at a Glance Guest User 9/8/12 Advocacy at a Glance Guest User 9/8/12 Congress Back in Session Next Week and more Read More
Uncategorized Guest User 9/4/12 Uncategorized Guest User 9/4/12 Sequestration Potentially to INCLUDE Industry User Fees Read More
Analysis and Commentary Guest User 8/24/12 Analysis and Commentary Guest User 8/24/12 Bringing IT at the FDA into the 21st Century Read More
Advocacy at a Glance Guest User 8/24/12 Advocacy at a Glance Guest User 8/24/12 Update on FY 13 Continuing Resolution and Congressional Deficit Negotiations and more Read More
Analysis and Commentary Guest User 8/20/12 Analysis and Commentary Guest User 8/20/12 Relative -- as Opposed to Absolute -- Levels of FDA Funding Read More
Analysis and Commentary Guest User 8/13/12 Analysis and Commentary Guest User 8/13/12 Honest assessment of priorities: a Congressional imperative for FDA Read More
Advocacy at a Glance Guest User 8/13/12 Advocacy at a Glance Guest User 8/13/12 President Obama signs Sequestration Transparency Act and more Read More
Advocacy at a Glance Guest User 8/8/12 Advocacy at a Glance Guest User 8/8/12 Betting on a 6-Month-Long, CR-based Compromise Read More
Advocacy at a Glance Guest User 8/8/12 Advocacy at a Glance Guest User 8/8/12 Office of Management and Budget Guidance to Government Agencies Regarding Potential Sequestration and more Read More
